Press Releases

November 5, 2020
-   P ositive P hase 3 d ata for   o devixibat in PFIC with filings on track for no later than early 202 1 - -   Phase 3 PFIC data accepted as late breakers at upcoming AASLD Meeting - - Introduces new and novel bile acid modulator A3907 at AASLD - -   Raised $160 million in gross proceeds in
October 23, 2020
- Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases- - Scientific leadership demonstrate s c ompany’s   commitment to increase understanding of   rare pediatric cholestatic liver disease s and reduce burden   of illness - BOSTON ,
October 5, 2020
Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases BOSTON , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing
October 2, 2020
BOSTON , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’s common
September 9, 2020
BOSTON , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common